Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The effectiveness of two combined option therapies (palbociclib-letrozole and palbociclib-fulvestrant) as first-line treatments for HR positive / HER2 -negative metastatic breast cancer

Next Previous
Trial Profile

The effectiveness of two combined option therapies (palbociclib-letrozole and palbociclib-fulvestrant) as first-line treatments for HR positive / HER2 -negative metastatic breast cancer

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palbociclib (Primary) ; Fulvestrant; Letrozole
  • Indications Advanced breast cancer; HER2 negative breast cancer
  • Focus Therapeutic Use
  • Acronyms PARSIFAL-LONG

Most Recent Events

  • 12 Dec 2023 New trial record
  • 06 Dec 2023 According to a MEDSIR Media Release, data from this study were presented at the 46th San Antonio Breast Cancer Symposium conference by Dr. Antonio Llombart-Cussac
  • 06 Dec 2023 Results presented in a MEDSIR Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top